港股再度调整，恒生生物科技指数逆势上涨，恒生医药ETF（159892）涨超1%

Group 1 - The core viewpoint of the article highlights the resilience of the Hong Kong biotechnology sector, particularly the Hang Seng Biotechnology Index, which is experiencing an upward trend despite broader market adjustments [1] - The Hong Kong Stock Exchange announced plans to launch Hang Seng Biotechnology Index futures on October 14, 2023, with trading set to begin on November 28, 2025, providing investors with precise risk management tools [1] - The introduction of index futures will make the Hang Seng Biotechnology Index the only index in the Hong Kong stock market with index futures in the pharmaceutical and healthcare sector [1] Group 2 - According to Shenwan Hongyuan, China has become the global leader in the number of clinical trials for innovative drugs over the past decade, transitioning from a "fast follower" to an "innovation leader" in research and development [1] - Domestic pharmaceutical companies are leveraging significant advantages in research and development efficiency, with extensive investments in new targets, new technology platforms, and challenging indications [1]